KALA BIO, Inc. — Director's Dealing 2017

Jul 26, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-25

Reporting Person: Grunberg Gregory (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-07-25	Common Stock	C	2055946	—	Acquired	2055946	Indirect
2017-07-25	Common Stock	P	215000	$15	Acquired	2270946	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-25	Series C Preferred Stock	$	C	10707985	Disposed		Common Stock (2055946)	Indirect

Footnotes

F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3: Includes 215,000 shares of Common Stock acquired by Longitude Venture Partners, II, L.P in the Issuer's initial public offering.

F4: These shares were held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.